Physician profile
Joseph F Eickmeyer
NPI 1073506176
$7,188.28
in general payments reported to CMS, 2019-2025
32 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $393 · 2021: $272 · 2022: $1,330 · 2023: $1,789 · 2024: $1,470 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,219.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $820.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $698.04 | 2020-2025 | Otezla, Repatha, Repatha |
| Axsome Therapeutics, INC. | $391.21 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $352.70 | 2019-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.73 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $230.27 | 2024-2025 | Voquezna |
| Optinose US, INC. | $203.51 | 2019-2020 | |
| Pfizer INC. | $154.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.04 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $138.49 | 2023-2025 | Gemtesa |
| Nevro Corp. | $127.05 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $125.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $123.24 | 2019 | |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.09 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $116.11 | 2020-2022 | |
| Coala Life INC | $114.47 | 2022 | |
| Siemens Medical Solutions USA, INC. | $112.34 | 2024-2025 | Cios Flow |
| Alkermes, INC. | $108.80 | 2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $106.74 | 2019-2024 | Spravato |
| Neurocrine Biosciences, INC. | $98.30 | 2024 | Ingrezza |
| Stryker Corporation | $94.23 | 2025 | Blueprint Patient Specific Instrumentation |
| Abbott Laboratories | $67.44 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $47.96 | 2019-2021 | |
| Lilly USA, LLC | $25.21 | 2024 | Mounjaro |
| Verona Pharma, INC. | $20.80 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $19.75 | 2022 | |
| Neurelis, INC. | $15.22 | 2023 | Valtoco |
| Dexcom, INC. | $15.07 | 2024 | Dexcom G6 Transmitter |
| Valinor Pharma, LLC | $13.47 | 2024 | Movantik |
| Organon LLC | $10.05 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Eickmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.